Clinical Trial Search

Phase 3 N=355 Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Chemotherapy for Acute Lymphoblastic Leukemia

Invasive Fungal Disease

Primary: Percentage of Participants With Proven or Probable IFIs During Remission-induction Chemotherapy for Acute Lymphoblastic Leukemia (ALL) — 7.9; 11.7 percentage of…

Gilead Sciences Results Apr 2015 33.0% serious AE View details

Phase 3 N=416 Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactivated Split Influenza Vaccine in Healthy Korea Children

Healthy

Primary: Percentage of Participants With Healthy Children Aged From 6 Months to <18 Years With Seroconversion — 62.02; 76.81; 53.41; 57.35 percentage of paticipants

Il-Yang Pharm. Co., Ltd. Results Apr 2015 1.9% serious AE View details

Phase 3 N=656 Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)

Advanced Gastric Cancer

Primary: Overall Survival (OS) — 5.39; 4.34 Months

Novartis Pharmaceuticals Results Apr 2015 45.9% serious AE View details

Phase 3 N=40 Ozurdex for Retinal Vein Occlusion Study (ORVO Study)

Retinal Vein Occlusion

Primary: Number of Participants Who Had a >30% Decrease in the Aqueous Levels of Various Vasoactive Proteins 4 Weeks After an Injection of Ozurdex — 7; 5; 7; 4 participants

Johns Hopkins University Results Apr 2015 7.5% serious AE View details

Phase 3 N=161 Cranial Stimulation for Chemotherapy Symptoms in Breast Cancer

Anxiety Disorder · Breast Cancer · Depression

Primary: Effects of CES as Compared to Sham CES on Symptoms of Depression, Anxiety, Fatigue, Pain and Sleep Disturbances in Women Receiving Adjuvant Chemotherapy for Early-stage…

Virginia Commonwealth University Results Apr 2015 0.7% serious AE View details

Phase 3 N=1,363 Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) for Metformin Background Patients — -1.19; -1.08; -0.62; -0.66 % change from baseline — p=<0.0001

Boehringer Ingelheim Results Apr 2015 5.4% serious AE View details

Phase 3 N=186 Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia

Schizophrenia

Primary: Overall Relapse Rate (in Percent) From Randomization to Exacerbation of Psychotic Symptoms/Impending Relapse. — 19.39; 37.50 relapse rate(percentage of participants)…

Otsuka Pharmaceutical Development &… Results Apr 2015 2.5% serious AE View details

Phase 3 N=80 Efficacy and Mechanisms of Pharmacologic Treatment of Fecal Incontinence

Fecal Incontinence

Primary: 7-day Bowel Diary, Number of Fecal Incontinence Episodes — 7.3; 7.9; 4.8; 4.1 Fecal incontinence episodes

US Department of Veterans Affairs Results Apr 2015 0.7% serious AE View details

Phase 3 N=608 Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome

Marfan Syndrome

Primary: Annual Rate of Change in Aortic Root (Sinuses of Valsalva) Body-surface-area-adjusted Z-score — -0.139; -0.107 z-score/year — p=0.08

Carelon Research Results Apr 2015 9.9% serious AE View details

Phase 3 N=641 Oral Treatment for Orthopaedic Post-operative Pain With Dexketoprofen Trometamol and Tramadol Hydrochloride

Acute Pain

Primary: SPID8 (Sum of Pain Intensity Differences Over 8 Hours) — 246.9; 208.8; 204.6; 151.1 units on a scale

Menarini Group Results Apr 2015 1.1% serious AE View details

Phase 3 N=606 Oral Treatment for Gynaecological Post-operative Pain With Dexketoprofen Trometamol and Tramadol Hydrochloride

Acute Pain

Primary: SPID8 (Sum of Pain Intensity Differences Over 8 Hours) — 241.8; 184.5; 157.3; 117.0 units on a scale

Menarini Group Results Apr 2015 1.7% serious AE View details

Phase 3 N=74 Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia

Schizophrenia

Primary: Percentage of Participants Reporting Treatment Emergent Adverse Events (TEAEs), Severe TEAEs, Discontinued Investigational Medicinal Product (IMP) Due to AEs, Serious…

Otsuka Pharmaceutical Development &… Results Mar 2015 6.8% serious AE View details

Phase 3 N=405 3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis

Allergic Rhinitis

Primary: Adverse Events Report — 124; 37 event

Meda Pharmaceuticals Results Mar 2015 0.3% serious AE View details

Phase 3 N=527 Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis

Aspergillosis · Invasive Fungal Infection

Primary: All-cause Mortality Through Day 42 — 18.6; 20.2 percentage of participants

Astellas Pharma Inc Results Mar 2015 54.8% serious AE View details

Phase 3 N=1,032 Newborn Ventilation in the Delivery Room: Could it be Improved With a T-piece Resuscitator?

Resuscitation

Primary: Proportion of Infants With a HR ≥ 100 Bpm at 2 Minutes of Life. — 93.7; 88; 93 percentage of participants

Edgardo Szyld Results Mar 2015 2.5% serious AE View details